First Parkinson's disease under tongue containing tablets approved by the FDA

23 (UPI) -- The Michael JFox Parkinson's Disease Research Foundation (MJFF) announced wednesday that the FDA has approved the treatment of Parkinson's disease in Kynmobi, developed by SunovionThe treatment is designed to treat people with Parkinson's disease who have not been effectively alleviated with oral therapy and who are experiencing a "shutdown" periodThis is the second approved treatment funded by MJFFAccording to Sunovion's official website, Kynmobi is the first under-the-line treatment approved for people with Parkinson's diseaseParkinson's disease is a chronic neurodegenerative disease that has about 6 million patients worldwideThere is no cure for Parkinson's disease, and patients often need to be treated with levodopa instead of lost dopamineLong-term use of this drug can lead to severe movement fluctuationsThis fluctuation is divided into two stages - during the "open" period, the patient's motor ability is normal, while during the "closed" period, the patient's motor ability is significantly reduced, usually manifested as slow movement, stiffness, walking disorder, tremor and unstable posture, greatly affecting the patient's daily lifeKynmobi is a quial-based aphomorphine film preparation placed under the tongueA 2014 MJFF survey of more than 3,000 people with Parkinson's disease found that more than 60 percent of respondents experienced a shutdown period of two hours or more a day, and nearly 50 percent said they experienced a shutdown period that severely affected their daily activitiesthe results of a Phase 3 clinical trial published in Lancet Neurology showed a significant improvement in motor symptoms in patients with Parkinson's disease treated withKynmobi within 30 minutes of the 12th week of administration, with an average 7.6 point reduction in the Part 3 score of the Comprehensive Parkinson's Disease Scale (MDS-UPDRS) compared to patients in the placebo groupInitial clinical improvement sprees can be observed within 15 minutes of administrationIn addition, patients treated with Kynmobi had significantly higher percentages of patients who had a full "open" period of patient assessment within 30 minutes of the 12th week than patients in the placebo group" research on Parkinson's disease continues and MJFF is proud of Kynmobi's approval," said Dr Todd Sherer, chief executive of MJFF"
we understand how much this closure period is affected and we are pleased to have developed a new treatment to help people with Parkinson's reintegration," said Dr Antony Loebel, Chief Executive Officer of Sunovion "
References: Retrieved 2020-05-22, from https://